Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Financial Officer | July 28, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 233,421 |
Reported balance
After 2026-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 31,667 · Balance 233,421 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 212,204 |
Reported balance
After 2026-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-29 · Sale · Disposed 21,217 · Balance 212,204 F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2021 Filed Sep 30, 2021 17:43 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058246 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,791 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 28, 2021 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 373 shares acquired on May 20, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 808 | $6.68 | $5,397.44 |
DisclosureSEC source: 0001209191-21-004101 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,751 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 78,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002086 · doc4.xml · derivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-01-04 F4 · derivative.exercise_date: One-third of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,787 | $5.80 | $16,164.60 |
DisclosureSEC source: 0001209191-21-002086 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,559 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002086 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,346 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 15, 2019, 33.33% of which vested on January 4, 2021 upon the achievement of a non-financial performance goal. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 64,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002086 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,563 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.